...A. We sustained this success through consistent investment in science, reinvesting over 30% of our revenues into R&D. This is well above the industry average, and it demonstrates our faith in our science, our research, and our tremendous team of innovators. B. Nearly 90% of drugs that enter clinical trials fail to reach the market, and today the average cost of developing a new drug exceeds $2 billion. C. To date, we have secured regulatory approval for 14. D. Our long-term commitment to science has resulted in four blockbuster commercial medicines which placed the company in a strong financial position. E. In the first quarter of 2025, our total revenues reached $3.03 billion with non-GAAP diluted earnings per share at [$8.22]. F. First quarter of 2025 net product sales grew 20% globally on a constant currency basis versus the first quarter of 2024, reflecting strong growth across all approved indications in all age groups and in all geographic regions. G. In the US, where net product...
